Diabetes

Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous cardiovascular disease.

Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.

The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.

Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.

A Senate Committee has voted to require drug companies to justify steep drug price hikes to the federal government; Pfizer has added former FDA Commissioner Scott Gottlieb, MD, to its board of directors; the FDA warned consumers of potential cybersecurity risks associated with certain mini Medtronic insulin pumps.

Diabetes is a self-managed disease, which makes the role of diabetes education crucial in order for patients to succeed in managing their disease, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included a report finding slow progress in reducing low-value care; a study finding savings by accountable care organizations may be overstated; CMS proposing a rule to allow for electronic prior authorization in Part D drugs.

Collaboration between cardiologists and endocrinologists are necessary when caring with patients with diabetes who have had cardiovascular issues in the past, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.

Merck's Center for Observational and Real-World Evidence has spent several years gathering evidence on clinical inertia and is now working on solutions to overcome it at the point of care.

The FDA's approval of the glucagon-like peptide receptor agonist marks the first non-insulin drug approved for youth with type 2 diabetes since the approval of metformin for pediatric use in 2000.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Diabetes educators can help patients with diabetes who face financial challenges make appropriate choices and receive assistance to afford medications, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.

There was something for everyone at the American Diabetes Association (ADA) Scientific Sessions, held June 7-11, 2019, in San Francisco, California.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

This week, the top managed care news included the Community Oncology Alliance submitting an alternative to the Oncology Care Model; more study results demonstrating diabetes drugs can prevent renal failure; US task force recommending pre-exposure prophylaxis for HIV prevention.

Selected technology news briefs from the 79th Scientific Sessions of the American Diabetes Association.

The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.

The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.

The observational study will use information from 3 databases to compare the SGLT2 inhibitor to a competing class of therapy for type 2 diabetes. Early cardiovascular and safety data were presented Monday at the 79th Scientific Sessions of the American Diabetes Association.

In an era when healthcare is extremely expensive, there are many opinions on how involved our federal government should be in bringing drug prices down. However, there is one particular drug-pricing crisis that many can agree needs to be addressed sooner rather than later: the insulin crisis.

Findings reported at the 79th Scientific Session of the American Diabetes Association in San Francisco, California, show the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.

Results from a study involving adding sitagliptin and increasing doses of metformin for patients who cannot attain glycemic control show that as glycated hemoglobin increases, it becomes harder to reach targets.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Oral semaglutide would be the first non-injectable agent in the GLP-1 receptor agonist class; these drugs produce powerful glycemic control along with weight loss.